Seven2 and HRK LUNIS Announce Successful Double Closing
Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120.
The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive range of services, including discretionary wealth management, advisory, institutional asset management and fund management, private equity, and family office services (through its multi-family office WERTIQ). It operates on a fully integrated platform with a central investment office and a common IT infrastructure.
The merger with Grossbötzl, Schmitz & Partner also underscores HRK LUNIS's active acquisition strategy and strengthens its regional presence. The merger with the renowned and long-established wealth manager is a further active contribution to the necessary consolidation of the still fragmented market of independent wealth managers. Both transactions, whose closing was originally expected in Q4 2025 and Q1 2026 respectively, were completed faster than planned after all necessary regulatory approvals were granted.
Andreas Brandt, CEO and co-founder of HRK LUNIS, who retains a significant ownership stake in the company, is pleased with the smooth handling of the double closing: “With Seven2 as our partner, we are perfectly positioned to drive our planned organic and inorganic growth and to consolidate and expand our position as a leading independent wealth manager in the DACH region. The merger with Grossbötzl, Schmitz & Partner is also an important strategic step to strengthen our presence in North Rhine-Westphalia and to actively shape the consolidation of the market.”
Dr. Florian Wolff, Partner at Seven2 and Head of the DACH Region, adds: “As our first acquisition in Germany, the merger of HRK LUNIS is a key strategic milestone for us. We are open to further external growth steps with independent financial service providers or advisory teams in the DACH region. Together, we want to further develop the company's profile, expand the product offering - including alternative investments - and optimize digital capabilities to create maximum value for clients.”
The financial details of the transactions were not disclosed.
About HRK LUNIS
With assets under management of approximately €7.5 billion, HRK LUNIS is one of the largest independent wealth managers in the German-speaking region. 120 employees handle the needs of sophisticated private clients, entrepreneurs, and their families. In the institutional sector and fund management, the company is responsible for the assets of companies, foundations, associations, and pension funds. HRK LUNIS distinguishes itself from competitors primarily through its in-house investment office with 19 trained analysts and fund managers. The expertise in private equity, which has grown over more than 20 years, is another unique selling proposition. The offering is complemented by the independently operating multi-family office WERTIQ. The wholly owned subsidiary of HRK LUNIS offers clients individual added value that goes beyond purely financial matters. The focus is on strategic asset planning, overall wealth controlling, digital financial accounting, as well as retirement and generational planning, and foundation management. In-house real estate experts assist with topics such as real estate acquisition or sale. The Munich-based company also conducts beauty contests for private, institutional, and sustainable wealth management mandates. More information can be found at www.hrklunis.de
About Seven2
Seven2 is an independent European private equity firm that is fully owned by its partners and finances SMEs and midcaps across Europe. It invests in high-potential companies in its main sectors of specialization: Tech & Telecom and Services. Seven2 empowers entrepreneurs with the expertise, practical support, and investment they need to achieve long-lasting sustainable growth. Seven2, formerly Apax Partners SAS, is headquartered in Paris and has offices in Milan, Amsterdam, and Munich.
Follow us: www.seven2.eu | Seven2 | @seven2_pe
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917496873/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom